With the outbreak of COVID-19, the most severe pandemic in the 21st century so far, a feverish search for therapeutic treatment and vaccinations has just started. A substantial number of approaches are focusing on the coronavirus S glycoprotein, a surfaceexposed protein that mediates the entry of the virus into the host cells. The Spike Glycoprotein might be the best suited target for the production of therapies and vaccine candidates. On April 27th, 2020 the Milken
Institute COVID-19 tracker listed 28 vaccines based on inactivated viruses, virus-like particles (VLP) or non-replicating viral vectors and 28 protein subunit approaches.
The aim of this technical note is to provide a description of the capture and subsequent purification of glycoproteins. Case studies are given for monoclonal antibodies and other glycoproteins, incl. the SARSCoV2 Spike glycoprotein.